Twist Bioscience Corporation Provides Revenue Guidance for the First Quarter, Fourth Quarter and Full Fiscal Year of 2024
For the fourth quarter, the company expects total revenue of approximately $78 million, Loss from operations of $38 to $40 million, excluding any one-time adjustments.
For the full fiscal year, the company expects total revenue to be in the range of $285 million to $290 million, growth of 16% to 18%, Loss from operations before taxes of approximately $180 to 188 million, a decrease of 15% to 18%.